Table 1 Clinical and histopathological variables of all ten cohorts.

From: SFRP4 gene expression is increased in aggressive prostate cancer

Clinical variables

Study cohort

IHC cohort

Erho et al.

TCGA-PRAD

CAM Ross-Adams et al.

Samples (patients)

156 (41)

40 (40)

545 (545)

549 (497)

186 (163)

Cancer samples (patients)

116 (41)

40 (40)

545 (545)

497 (497)

112 (112)

 Age at diagnosis, years (median, range)

64 (48–69)

61 (48–73)

65.3 ± 6.4

61 (41–78)

61 (41–73)

 PSA before surgery, ng/mL (median, range)

9.1 (4.0–45.8)

8.85 (5.2–18)

—

7.4 (0.7–107)

7.8 (3.2–23.7)

 Grade Groups

  Low (1–2)

60 (52%)

19 (47.5%)

334 (61%)a

207 (42%)

82 (73%)

  High (3–5)

56 (48%)

21 (52.5%)

211 (39%)a

289 (58%)

30 (27%)

Pathological T stage

 pT1

—

—

—

—

—

 pT2

70 (60%)

27 (68%)

219 (40%)

187 (38%)

33 (29%)

 pT3

40 (35%)

12 (30%)

253 (47%)

293 (59%)

74 (66%)

 pT4

—

—

 

9 (2%)

1 (1%)

 No data

6 (5%)

1 (2%)

73 (13%)

8 (1%)

4 (4%)

Follow-up

 Endpoint

BCR

BCR

Metastasis

BCR

Recurrence

  Occurred

13 (32%)

16 (40%)

212 (39%)b

91 (18%)

19 (17%)

  Not occurred

21 (51%)

21 (53%)

333 (69%)b

399 (80%)

93 (83%)

  No data

7 (17%)

3 (8%)

—

7 (2%)

—

Clinical variable

STK Ross-Adams et al.

Wang et al.

Sboner et al.

Taylor et al.

Mortensen et al.

Samples (patients)

94 (94)

136 (82)

281 (281)

160 (131)

50 (50)

 Cancer samples (patients)

94 (94)

65 (56)

281 (281)

131 (131)

36 (36)

 Age years (median, range)

 

63 (43–77)

74 (51–91)

58 (37–73)

63 (46–71)

 PSA before surgery, ng/mL (median, range)

7.95 (1.5–117)

 

6.62 (1.0–75)

5.92 (1.0–46)

16 (5.0–43)

 Grade Groups

  Low (1–2)

60 (64%)

50 (77%)

162 (58%)

107 (82%)

32 (89%)a

  High (3–5)

34 (36%)

15 (23%)

119 (42%)

24 (18%)

4 (11%)a

Pathological T-stage

 pT1

—

1 (2%)

281c (100%)

—

—

 pT2

48 (51%)

32 (57%)

—

85 (65%)

19 (53%)

 pT3

42 (45%)

20 (35%)

—

40 (30%)

17 (47)

 pT4

—

1 (2%)

—

6 (5%)

—

 No data

4 (4%)

2 (2%)

—

—

—

Follow-up

 Endpoint

Recurrence

BCR

PCa-death

BCR

BCR

  Occurred

45 (48%)

29 (52%)

165 (59%)

27 (21%)

22 (61%)

  Not occurred

48 (51%)

27 (48%)

116 (41%)

104 (79%)

14(39%)

  No data

1 (1%)

—

—

—

—

  1. Abbreviations: BCR – biochemical recurrence, PCa-death – prostate cancer-specific death.
  2. aIn Erho et al. and Mortensen et al.: Low Grade Group 1–3 and high Grade Group 4–5 (due to lack of information to separate Grade Group 2 and 3).
  3. bIn Erho et al. metastatic progression at 10-year patient follow-up.
  4. cClinical T-stage.
Back to article page